MOG (35-55)

Biological Activity

MOG (35-55) or myelin oligodendrocyte glycoprotein (MOG) 35-55 is a minor component of CNS myelin. MOG (35-55) produces a relapsing-remitting neurological disease with extensive plaque-like demyelination, common to the manifestations of multiple sclerosis. MOG (35-55) induces strong T and B cell responses and is highly encephalitogenic. MOG (35-55) induces T cell-mediated multiple sclerosis in animal models. When co-administered with ITE, MOG (35-55) induces tolerogenic dendritic cells and suppresses disease development in mouse preclinical models of multiple sclerosis.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Analysis of the fine B cell specificity during the chronic/relapsing course of a multiple sclerosis-like disease in Lewis rats injected with the encephalitogenic myelin oligodendrocyte glycoprotein peptide 35-55.
   Ichikawa et al.
   J.Immunol., 1996;157:919
2. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein.
   Slavin et al.
   Autoimmunity, 1998;28:109
3. T cell and antibody responses in remitting-relapsing experimental autoimmune encephalomyelitis in (C57BL/6xSJL) F1 mice.
   Zhang et al.
   J.Neuroimmunol., 2004;148:1
4. TAGAP instructs Th17 differentiation by bridging Dectin activation to EPHB2 signaling in innate antifungal response
   J Chen, R He, W Sun, R Gao, Q Peng, L Zhu, Y Du, X Ma, X Guo, H Zhang, C Tan, J Wang, W Zhang, X Weng, J Man, H Bauer, QK Wang, BN Martin, CJ Zhang, X Li, C Wang
   Nat Commun, 2020;11(1):1913.

Product Datasheets